There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX), Exelixis (EXEL) and Hologic (HOLX) with bullish sentiments.
Dynavax (DVAX)
In a report released yesterday, Matt Phipps from William Blair maintained a Buy rating on Dynavax. The company’s shares closed last Friday at $4.99.
According to TipRanks.com, Phipps is a 1-star analyst with an average return of -2.3% and a 37.4% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Atara Biotherapeutics.
Dynavax has an analyst consensus of Moderate Buy, with a price target consensus of $14.00, which is a 186.9% upside from current levels. In a report issued on December 23, H.C. Wainwright also reiterated a Buy rating on the stock with a $14.00 price target.
See today’s analyst top recommended stocks >>
Exelixis (EXEL)
William Blair analyst Andy Hsieh reiterated a Buy rating on Exelixis on January 4. The company’s shares closed last Friday at $22.82.
According to TipRanks.com, Hsieh is a 4-star analyst with an average return of 15.4% and a 57.5% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Nektar Therapeutics, and Beyondspring.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Exelixis with a $30.29 average price target, implying a 33.6% upside from current levels. In a report issued on December 22, Oppenheimer also assigned a Buy rating to the stock with a $35.00 price target.
Hologic (HOLX)
Raymond James analyst Jayson Bedford maintained a Buy rating on Hologic today. The company’s shares closed last Friday at $80.49, close to its 52-week high of $80.52.
According to TipRanks.com, Bedford is a 5-star analyst with an average return of 16.3% and a 73.4% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Merit Medical Systems, and Edwards Lifesciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Hologic with a $90.11 average price target, an 11.9% upside from current levels. In a report released today, BTIG also maintained a Buy rating on the stock with a $84.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
